(EVLO) – Company Press Releases
-
Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
-
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
-
Evelo Biosciences Closes $25.5 Million Private Placement
-
Evelo Biosciences Announces $25.5 Million Private Placement
-
Evelo Biosciences Announces Reverse Stock Split Effective
-
Alltrna Engineers tRNA Oligonucleotide with Improved Potency and Activity for In Vivo Readthrough of Premature Termination Codons
-
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
-
Evelo Biosciences Provides Clinical Updates
-
Evelo Biosciences Provides Clinical Updates
-
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
-
Evelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023
-
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
-
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference
-
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
-
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial
-
Evelo Biosciences Provides Clinical and Business Updates
-
Evelo Biosciences Provides Clinical and Business Updates
-
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update
-
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
-
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
-
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
-
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
-
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
-
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
-
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
-
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
-
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
-
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
-
Evelo Biosciences Announces Grant of Inducement Award
-
Evelo Biosciences Announces Grant of Inducement Award
-
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
-
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
-
Senda Biosciences Announces Close of $123 Million Series C Financing
-
Evelo Biosciences Announces Succession Plan
-
Evelo Biosciences Announces Succession Plan
-
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
-
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
-
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
-
Evelo Biosciences to Announce Second Quarter 2022 Financial Results on Thursday, August 11, 2022
-
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
-
Evelo Biosciences Announces Appointment of Marella Thorell as Chief Financial Officer
-
Cytovia Therapeutics Appoints Luca Scavo as Chief Financial Officer and James Priour as Chief Product Officer
-
Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock
-
Evelo Biosciences Announces $79.2 Million Registered Direct Offering of Common Stock
-
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
-
CORRECTION: Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
-
Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
-
Evelo Biosciences Announces First Quarter 2022 Financial Results and Business Highlights
Back to EVLO Stock Lookup